Cancer
Credibility 94
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
June 6, 2026 · The Lancet. Oncology
Key takeaway
This study found a new treatment that could help Black men with prostate cancer live longer without their cancer coming back. It's important because prostate cancer disproportionately affects our community, and this treatment showed promise without major side effects.
Why this matters for our communities
Research in cancer helps close long-standing gaps in how Black and African American families are studied, diagnosed, and cared for. Use findings like this one to start informed conversations with your care team — not as a substitute for personal medical advice.
More in Cancer
February 1, 2027Dual-modal immunoassay for prostate cancer-derived exosomes enabled by a black phosphorus/silver SERS substrate and Yb/Er co-doped NaGdF4 UCL nanoprobes.Read December 18, 2026Factors Associated with Screening Mammography Utilization Among Women Veterans in VA Primary Care.Read November 16, 2026Characterizing prior symptomatic emergency department visits among patients undergoing unplanned colon cancer surgery.Read